Net cash flipped to $11.5m net debt as continuing PBT fell 17.3%

The cleaner read is PBT, which fell 17.3% to $22.4m, and operating profit (EBIT), which fell 7.3% to $31.8m on revenue growth of 2.1% to $503.9m. Management attributes the operating-profit decline to inflation, softer retail spending and reduced higher-margin COVID-19 activity.

The more important shift sits on the balance sheet. Cash fell $34.8m to $23.4m, gross borrowings rose 48.5% to $34.9m, and the group moved from a $34.7m net cash position to $11.5m net debt — a swing of roughly $46m despite operating cash flow holding flat at $46.0m. The final dividend was cut 42.9% to 2.0 cents.

• Operating cash flow held flat at $46.0m and FCF pre-lease was $38.6m, yet cash reserves fell $34.8m and borrowings rose $11.4m. With equity down $35.4m against $11.8m of earnings, distributions, lease payments and other financing absorbed materially more cash than the business generated. This matters because it is the financing posture, not the P&L, that drove the dividend cut.

• Continuing-operations earnings are softening, not just comparable-period noise. Profit from continuing operations fell from $20.3m to $15.8m and PBT fell 17.3%, with both reportable segments going backwards: Pharmacy Services result dropped to $19.3m from $21.1m and Medical Services to $15.0m from $16.2m. The implication is that the underlying earnings base supporting future dividends is weaker, independent of the discontinued-operation accounting.

• Working capital absorbed cash. Operating working capital rose $8.3m to $54.0m and receivable days lengthened from 10.1 to 17.0, partly reflecting a new $12.5m contract-asset balance. Inventory days were broadly flat. This is a structural step-up in funding requirement that competes directly with capex (up 29.5% to $7.4m) and shareholder returns.

The HY24 split shows revenue weighted 49.6% to the first half and NPAT 47.7%, so the year was close to evenly weighted rather than second-half loaded — there is no implied seasonal tailwind to lean on.

What the release does support is that the FY24 operating run-rate is below FY23 across both segments and that financing capacity is now tighter, so a return to FY23 earnings levels would require either margin recovery against the cited inflation and retail headwinds or balance-sheet improvement before further capital return is realistic.

Operating cash flow of $46.0m comfortably exceeded NPAT of $11.8m (FCF/NPAT 328.0%), but that conversion ratio is flattered by the discontinued-operation drag in NPAT and by the working-capital and contract-asset movements that pushed receivable days higher. Capex intensity at 1.5% of revenue remains modest, and free cash flow pre-lease was $38.6m versus $40.2m prior — a more representative read of underlying cash generation than the conversion ratio suggests.

The effective tax rate rose to 29.4% from 25.1%, explaining part of the gap between EBIT down 7.3% and PBT down 17.3%, but this is a modest distortion rather than the main story. The economically durable issues are the segment margin compression (Pharmacy Services result margin compressed in derived terms, Medical Services likewise), the $8.3m working-capital build, and the financing-led balance-sheet weakening — all of which point to a lower-quality result than the flat operating cash flow line suggests in isolation.

This briefing cannot assess management's stated outlook, segment-level strategic plans, or any non-disclosed financing commitments, as none were provided in the supplied materials.